$691.51 Million in Sales Expected for DexCom, Inc. (NASDAQ:DXCM) This Quarter

Equities research analysts expect DexCom, Inc. (NASDAQ:DXCMGet Rating) to post sales of $691.51 million for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for DexCom’s earnings, with the lowest sales estimate coming in at $663.70 million and the highest estimate coming in at $716.41 million. DexCom posted sales of $595.10 million during the same quarter last year, which would indicate a positive year over year growth rate of 16.2%. The business is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that DexCom will report full year sales of $2.91 billion for the current year, with estimates ranging from $2.84 billion to $2.95 billion. For the next year, analysts expect that the business will post sales of $3.51 billion, with estimates ranging from $3.34 billion to $3.69 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow DexCom.

DexCom (NASDAQ:DXCMGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.18). DexCom had a return on equity of 12.42% and a net margin of 8.23%. The firm had revenue of $628.80 million for the quarter, compared to the consensus estimate of $623.97 million. During the same quarter last year, the business earned $0.33 earnings per share. The business’s revenue for the quarter was up 24.5% compared to the same quarter last year.

DXCM has been the topic of a number of research analyst reports. Citigroup lowered their price target on DexCom from $630.00 to $525.00 and set a “buy” rating on the stock in a report on Tuesday, May 17th. BTIG Research increased their price target on DexCom from $535.00 to $560.00 in a research report on Monday, April 18th. Canaccord Genuity Group decreased their price objective on DexCom from $525.00 to $500.00 in a research report on Friday, April 29th. StockNews.com assumed coverage on DexCom in a research note on Thursday, March 31st. They set a “hold” rating for the company. Finally, Bank of America started coverage on DexCom in a research note on Wednesday, March 2nd. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $541.65.

In other news, EVP Barry J. Regan sold 1,106 shares of the stock in a transaction dated Tuesday, March 29th. The shares were sold at an average price of $500.00, for a total transaction of $553,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Steven Robert Pacelli sold 250 shares of the firm’s stock in a transaction that occurred on Wednesday, February 23rd. The stock was sold at an average price of $394.33, for a total transaction of $98,582.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,009 shares of company stock worth $1,783,689. 0.41% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Mercer Global Advisors Inc. ADV increased its stake in DexCom by 17.8% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 2,587 shares of the medical device company’s stock valued at $1,415,000 after purchasing an additional 390 shares in the last quarter. CI Investments Inc. lifted its holdings in DexCom by 37.1% during the third quarter. CI Investments Inc. now owns 2,112 shares of the medical device company’s stock valued at $1,155,000 after purchasing an additional 571 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of DexCom by 43.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 6,263 shares of the medical device company’s stock valued at $3,425,000 after buying an additional 1,896 shares during the last quarter. B. Riley Wealth Management Inc. acquired a new stake in shares of DexCom in the third quarter valued at about $341,000. Finally, NorthRock Partners LLC increased its position in DexCom by 23.3% during the third quarter. NorthRock Partners LLC now owns 597 shares of the medical device company’s stock worth $326,000 after purchasing an additional 113 shares during the last quarter. 93.26% of the stock is owned by institutional investors.

Shares of NASDAQ DXCM opened at $321.23 on Monday. DexCom has a 1-year low of $302.61 and a 1-year high of $659.45. The company has a debt-to-equity ratio of 0.90, a current ratio of 5.27 and a quick ratio of 4.79. The business’s fifty day moving average price is $436.34 and its two-hundred day moving average price is $475.08. The firm has a market capitalization of $31.52 billion, a PE ratio of 155.18, a P/E/G ratio of 5.55 and a beta of 1.05.

DexCom shares are going to split on Friday, June 10th. The 4-1 split was announced on Friday, March 25th. The newly issued shares will be distributed to shareholders after the market closes on Thursday, June 9th.

About DexCom (Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Stories

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.